Skip to main content
Fig. 2 | BMC Pediatrics

Fig. 2

From: Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design

Fig. 2

Flow chart. Expected number of ALL patients in the DexaDays-2 study. ALL = acute lymphoblastic leukaemia. Group 1: starting with two courses hydrocortisone, thereafter cross over to placebo. Group 2: starting with two courses placebo, thereafter cross over to hydrocortisone

Back to article page